the endothelin axis in uterine leiomyomas: New insights

Biology of Reproduction

Volumn 87, Issue 1, 2012, Pages 5-

  Tanfin, Zahra ^a   Breuiller Fouche, Michelle ^a,b  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

Endothelin signal; Pathophysiology; Tumor growth; Uterine leiomyoma

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; SOMATOMEDIN; SPHINGOLIPID; SPHINGOSINE KINASE 1; TRANSCRIPTOME;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMAN; LIPID METABOLISM; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UTERUS MYOMA; ANIMAL; BIOLOGICAL MODEL; FEMALE; GENETICS; LEIOMYOMA; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW; UTERUS CANCER;

RATTUS;

ANIMALS; CELL PROLIFERATION; ENDOTHELIN-1; FEMALE; HUMANS; LEIOMYOMA; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; RATS; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; TRANSCRIPTOME; UTERINE NEOPLASMS;

EID: 84869238304     PISSN: 00063363     EISSN: 15297268     Source Type: Journal    
DOI: 10.1095/biolreprod.111.097725     Document Type: Article

References (117)

1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94:435-438.
2. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 2003; 111:1037-1054.
3. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22:571-588.
4. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science 2005; 308:1589-1592.
5. Marsh EE, Bulun SE. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am 2006; 33:59-67.
6. Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol 1992; 166:746-751.
7. Broekmans FJ. GnRH agonists and uterine leiomyomas. Hum Reprod 1996; 11(Suppl 3):3-25.
8. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med 2004; 22:105-111.
9. Maruo T, Ohara N, Wang J, Matsuo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum Reprod Update 2004; 10: 207-220.
10. Ciarmela P, Islam MS, Reis FM, Gray PC, Bloise E, Petraglia F, Vale W, Castellucci M. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update 2011; 17:772-790.
11. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010; 28:180-203.
12. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, Tang MS, Toniolo P. Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 2005; 20:852-863.
13. Ding L, Xu J, Luo X, Chegini N. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab 2004; 89:5549-5557.
14. Gao X, Yu L, Castro L, Moore AB, Hermon T, Bortner C, Sifre M, Dixon D. An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells. Toxicol Lett 2010; 196:133-141.
15. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 2002; 78:1-12.
16. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol 2006; 195:415-420.
17. Norian JM, Owen CM, Taboas J, Korecki C, Tuan R, Malik M, Catherino WH, Segars JH. Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma. Matrix Biol 2012; 31:57-65.
18. Rogers R, Norian J, Malik M, Christman G, Abu-Asab M, Chen F, Korecki C, Iatridis J, Catherino WH, Tuan RS, Dhillon N, Leppert P, et al. Mechanical homeostasis is altered in uterine leiomyoma. Am J Obstet Gynecol 2008; 198:474.e1-e11.
19. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011; 209:139-151.
20. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29:290-308.
21. Dou Q, Tarnuzzer RW, Williams RS, Schultz GS, Chegini N. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression. Mol Hum Reprod 1997; 3: 1005-1014.
22. Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol 2007; 23:541-546.
23. Malik M, Catherino WH. Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arrays. Fertil Steril 2007; 87:1166-1172.
24. Zbucka M, Miltyk W, Bielawski T, Surazynski A, Palka J, Wolczynski S. Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells. Folia Histochem Cytobiol 2007; 45(Suppl 1):S181-S185.
25. Morikawa A, Ohara N, Xu Q, Nakabayashi K, DeManno DA, Chwalisz K, Yoshida S, Maruo T. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 2008; 23:944-951.
26. Meidan R, Levy N. The ovarian endothelin network: an evolving story. Trends Endocrinol Metab 2007; 18:379-385.
27. Salamonsen LA, Marsh MM, Findlay JK. Endometrial endothelin: regulator of uterine bleeding and endometrial repair. Clin Exp Pharmacol Physiol 1999; 26:154-157.
28. Riley SC, Findlay JK, Salamonsen LA. Endothelin-1 and endothelin receptors are present in the sheep uterus and conceptus at implantation. J Endocrinol 1995; 147:235-244.
29. George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens 2011; 24:964-969.
30. Smollich M, Wulfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 2007; 5:239-248.
31. Olgun NS, Patel HJ, Stephani R, Lengyel I, Reznik SE. Blockade of endothelin-1 with a novel series of 1, 3, 6-trisubstituted-2-carboxyquinol-4-ones controls infection-associated preterm birth. Am J Pathol 2010; 177:1929-1935.
32. Tanfin Z, Leiber D, Robin P, Oyeniran C, Breuiller-Fouche M. Endothelin-1: physiological and pathological roles in myometrium. Int J Biochem Cell Biol 2011; 43:299-302.
33. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
34. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998; 9:378-383.
35. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003; 88:163-166.
36. Khimji AK, Rockey DC. Endothelin-biology and disease. Cell Signal 2010; 22:1615-1625.
37. Wang R, Dashwood RH. Endothelins and their receptors in cancer: identification of therapeutic targets. Pharmacol Res 2011; 63:519-524.
38. Nakajima K, Kubo S, Kumagaye S, Nishio H, Tsunemi M, Inui T, Kuroda H, Chino N, Watanabe TX, Kimura T, Sakakibara S. Structureactivity relationship of endothelin: importance of charged groups. Biochem Biophys Res Commun 1989; 163:424-429.
39. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, Yanagisawa M, Goto K, Masaki T. Structure-activity relationships of endothelin: importance of the C-terminal moiety. Biochem Biophys Res Commun 1988; 156:1182-1186.
40. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86:2863-2867.
41. Arinami T, Ishikawa M, Inoue A, Yanagisawa M, Masaki T, Yoshida MC, Hamaguchi H. Chromosomal assignments of the human endothelin family genes: the endothelin-1 gene (EDN1) to 6p23-p24, the endothelin-2 gene (EDN2) to 1p34, and the endothelin-3 gene (EDN3) to 20q13.2-q13.3. Am J Hum Genet 1991; 48:990-996.
42. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001; 41: 851-876.
43. Yanagisawa H, Hammer RE, Richardson JA, Emoto N, Williams SC, Takeda S, Clouthier DE, Yanagisawa M. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest 2000; 105:1373-1382.
44. Pekonen F, Nyman T, Rutanen EM. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma. Mol Cell Endocrinol 1994; 103:165-170.
45. Honore JC, Robert B, Vacher-Lavenu MC, Chapron C, Breuiller-Fouche M, Ferre F. Expression of endothelin receptors in human myometrium during pregnancy and in uterine leiomyomas. J Cardiovasc Pharmacol 2000; 36:S386-389.
46. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 264:14954-14959.
47. Stow LR, Jacobs ME, Wingo CS, Cain BD. Endothelin-1 gene regulation. Faseb J 2011; 25:16-28.
48. Malek AM, Greene AL, Izumo S. Regulation of endothelin 1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc Natl Acad Sci U S A 1993; 90:5999-6003.
49. Stricklett PK, Strait KA, Kohan DE. Novel regulation of endothelin-1 promoter activity by protein kinase C. Cell Biochem Biophys 2011; 61: 643-650.
50. Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, Molkentin JD, Meloche S, Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 2001; 15:2702-2719.
51. Raoch V, Rodriguez-Pascual F, Lopez-Martinez V, Medrano-Andres D, Rodriguez-Puyol M, Lamas S, Rodriguez-Puyol D, Lopez-Ongil S. Nitric oxide decreases the expression of endothelin-converting enzyme-1 through mRNA destabilization. Arterioscler Thromb Vasc Biol 2011; 31:2577-2585.
52. Yeligar S, Tsukamoto H, Kalra VK. Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microRNA-199. J Immunol 2009; 183:5232-5243.
53. Masaki T, Vane JR, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994; 46: 137-142.
54. Davenport AP, Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin Sci (Lond) 2002; 103(Suppl 48):1S-3S.
55. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-732.
56. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
57. Evans NJ, Walker JW. Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J 2008; 95:483-492.
58. Hosoda K, Nakao K, Hiroshi A, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S, Imura H. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287:23-26.
59. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of endothelin receptors in neuroendocrine cells. Front Neuroendocrinol 1996; 17:327-369.
60. Dokhac L, Le Stunff H, Naze S, Harbon S. ETA receptors mediate activation of phospholipases C and D in rat myometrium. J Cardiovasc Pharmacol 1995; 26(Suppl 3):S307-S309.
61. Breuiller-Fouche M, Heluy V, Fournier T, Ferre F. Endothelin receptors: binding and phosphoinositide breakdown in human myometrium. J Pharmacol Exp Ther 1994; 270:973-978.
62. Arthur P, Taggart MJ, Zielnik B, Wong S, Mitchell BF. Relationship between gene expression and function of uterotonic systems in the rat during gestation, uterine activation and both term and preterm labour. J Physiol 2008; 586:6063-6076.
63. Leiber D, Banno Y, Tanfin Z. Exogenous sphingosine 1-phosphate and sphingosine kinase activated by endothelin-1 induced myometrial contraction through differential mechanisms. Am J Physiol Cell Physiol 2007; 292:C240-C250.
64. Breuiller-Fouche M, Tertrin-Clary C, Heluy V, Fournier T, Ferre F. Role of protein kinase C in endothelin-1-induced contraction of human myometrium. Biol Reprod 1998; 59:153-159.
65. Naze S, Le Stunff H, Dokhac L, Thomas G, Harbon S. Activation of phospholipase D by endothelin-1 in rat myometrium. Role of calcium and protein kinase C. J Pharmacol Exp Ther 1997; 281:15-23.
66. Husain S, Abdel-Latif AA. Role of protein kinase C alpha in endothelin-1 stimulation of cytosolic phospholipase A2 and arachidonic acid release in cultured cat iris sphincter smooth muscle cells. Biochim Biophys Acta 1998; 1392:127-144.
67. Deacon K, Knox AJ. Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop. J Biol Chem 2010; 285:25913-25927.
68. Robin P, Boulven I, Desmyter C, Harbon S, Leiber D. ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. Am J Physiol Cell Physiol 2002; 283:C251-C260.
69. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007; 5: 45-52.
70. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3:110-116.
71. Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008; 86:473-484.
72. Wu MH, Lo JF, Kuo CH, Lin JA, Lin YM, Chen LM, Tsai FJ, Tsai CH, Huang CY, Tang CH. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/ mTOR pathways. J Cell Physiol 2012; 227:3016-3026.
73. Chahdi A, Sorokin A. Endothelin-1 induces p66Shc activation through EGF receptor transactivation: Role of beta(1)Pix/Galpha(i3) interaction. Cell Signal 2010; 22:325-329.
74. Rosano L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 2007; 67:6351-6359.
75. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106:1675-1680.
76. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001; 20:1594-1600.
77. Breuiller-Fouche M, Vacher-Lavenu MC, Fournier T, Morice P, Dubuisson JB, Ferre F. EndothelinA receptors in human uterine leiomyomas. Obstet Gynecol 1997; 90:727-730.
78. Breuiller-Fouche M, Heluy V, Fournier T, Dallot E, Vacher-Lavenu MC, Ferre F. Role of endothelin-1 in regulating proliferation of cultured human uterine smooth muscle cells. Mol Hum Reprod 1998; 4:33-39.
79. Weston G, Trajstman AC, Gargett CE, Manuelpillai U, Vollenhoven BJ, Rogers PA. Fibroids display an anti-angiogenic gene expression profile when compared with adjacent myometrium. Mol Hum Reprod 2003; 9: 541-549.
80. Maggi M, Vannelli GB, Fantoni G, Baldi E, Magini A, Peri A, Giannini S, Gloria L, Del Carlo P, Casparis D, Tomei T, Serio M. Endothelin in the human uterus during pregnancy. J Endocrinol 1994; 142:385-396.
81. Eude I, Dallot E, Vacher-Lavenu MC, Chapron C, Ferre F, Breuiller-Fouche M. Potentiation response of cultured human uterine leiomyoma cells to various growth factors by endothelin-1: role of protein kinase C. Eur J Endocrinol 2001; 144:543-548.
82. Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, Medina TM, Bradford AP. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril 2009; 91:2650-2663.
83. Eude I, Dallot E, Ferre F, Breuiller-Fouche M. Protein kinase Calpha is required for endothelin-1-induced proliferation of human myometrial cells. Biol Reprod 2002; 66:44-49.
84. Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology 2009; 150:2436-2445.
85. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146: 1568-1579.
86. Raymond MN, Robin P, De Zen F, Vilain G, Tanfin Z. Differential endothelin receptor expression and function in rat myometrial cells and leiomyoma ELT3 cells. Endocrinology 2009; 150:4766-4776.
87. Robin P, Chouayekh S, Bole-Feysot C, Leiber D, Tanfin Z. Contribution of phospholipase D in endothelin-1-mediated extracellular signalregulated kinase activation and proliferation in rat uterine leiomyoma cells. Biol Reprod 2005; 72:69-77.
88. Raymond MN, Bole-Feysot C, Banno Y, Tanfin Z, Robin P. Endothelin-1 inhibits apoptosis through a sphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology 2006; 147: 5873-5882.
89. Serrano-Sanchez M, Tanfin Z, Leiber D. Signaling pathways involved in sphingosine kinase activation and sphingosine-1-phosphate release in rat myometrium in late pregnancy: role in the induction of cyclooxygenase Endocrinology 2008; 149:4669-4679.
90. Tanfin Z, Serrano-Sanchez M, Leiber D. ATP-binding cassette ABCC1 is involved in the release of sphingosine 1-phosphate from rat uterine leiomyoma ELT3 cells and late pregnant rat myometrium. Cell Signal 2011; 23:1997-2004.
91. Oyeniran C, Tanfin Z. MAPK14 cooperates with MAPK3/1 to regulate endothelin-1-mediated prostaglandin synthase 2 induction and survival in leiomyoma but not in normal myometrial cells. Biol Reprod 2011; 84: 495-504.
92. Pan Q, Luo X, Chegini N. Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians. Reprod Biol Endocrinol 2007; 5:34.
93. Horinouchi T, Asano H, Higa T, Nishimoto A, Nishiya T, Muramatsu I, Miwa S. Differential coupling of human endothelin type A receptor to G(q/11) and G(12) proteins: the functional significance of receptor expression level in generating multiple receptor signaling. J Pharmacol Sci 2009; 111:338-351.
94. Lopez Bernal A. Mechanisms of labour-biochemical aspects. Bjog 2003; 110(Suppl 20):39-45.
95. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, Luscher TF. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89: 583-590.
96. Wang W, Yen H, Chen CH, Soni R, Jasani N, Sylvestre G, Reznik SE. The endothelin-converting enzyme-1/endothelin-1 pathway plays a critical role in inflammation-associated premature delivery in a mouse model. Am J Pathol 2008; 173:1077-1084.
97. Joseph DS, Malik M, Nurudeen S, Catherino WH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 2010; 93:1500-1508.
98. Khimji AK, Shao R, Rockey DC. Divergent transforming growth factorbeta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation. Am J Pathol 2008; 173:716-727.
99. Alvarez D, Briassouli P, Clancy RM, Zavadil J, Reed JH, Abellar RG, Halushka M, Fox-Talbot K, Barrat FJ, Buyon JP. A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block. J Biol Chem 2011; 286:30444-30454.
100. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012; 22: 50-60.
101. Zhou S, Yi T, Shen K, Zhang B, Huang F, Zhao X. Hypoxia: the driving force of uterine myometrial stem cells differentiation into leiomyoma cells. Med Hypotheses 2011; 77:985-986.
102. Moore AB, Yu L, Swartz CD, Zheng X, Wang L, Castro L, Kissling GE, Walmer DK, Robboy SJ, Dixon D. Human uterine leiomyoma-derived fibroblasts stimulate uterine leiomyoma cell proliferation and collagen type I production, and activate RTKs and TGF beta receptor signaling in coculture. Cell Commun Signal 2010; 8:10.
103. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res 2009; 19:128-139.
104. Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, Kimberland ML, Wilson E, Saraf KA, Liu W, McCampbell AS, Dave B, Broaddus RR, et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009; 69:6171-6178.
105. Luo X, Chegini N. The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma. Semin Reprod Med 2008; 26:500-514.
106. Pan Q, Luo X, Chegini N. microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.Mol Hum Reprod 2010; 16:215-227.
107. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14:44-50.
108. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxiainducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002; 277:27850-27855.
109. Hague S, Zhang L, Oehler MK, Manek S, MacKenzie IZ, Bicknell R, Rees MC. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiomyoma vascular density. Clin Cancer Res 2000; 6:2808-2814.
110. Wang W, Yen H, Chen CH, Jasani N, Soni R, Koscica K, Reznik SE. Prevention of inflammation-associated preterm birth by knockdown of the endothelin-1-matrix metalloproteinase-1 pathway. Mol Med 2010; 16:505-512.
111. Walker CL, Hunter D, Everitt JI. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003; 38:349-356.
112. Zaitseva M, Vollenhoven BJ, Rogers PA. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod 2006; 12:187-207.
113. Carney SA, Tahara H, Swartz CD, Risinger JI, He H, Moore AB, Haseman JK, Barrett JC, Dixon D. Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest 2002; 82: 719-728.
114. Malik M, Catherino WH. Development and validation of a threedimensional in vitro model for uterine leiomyoma and patient-matched myometrium. Fertil Steril 2012; (in press). Published online ahead of print 15 March 2012. DOI: 10.1016/j.fertnstert.2012.02.037.
115. Tsuiji K, Takeda T, Li B, Kondo A, Ito M, Yaegashi N. Establishment of a novel xenograft model for human uterine leiomyoma in immunodeficient mice. Tohoku J Exp Med 2010; 222:55-61.
116. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 2010; 151:2433-2442.
117. Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B, Baird DD. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105:19887-19892.